• Please log in or register to access this feature.

Rheumatoid Arthritis

You have full text access to this OnlineOpen article

Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice

  1. M. Blom1,*,
  2. W. Kievit1,
  3. H. H. Kuper2,
  4. T. L. Jansen3,
  5. H. Visser4,
  6. A. A. den Broeder5,
  7. H. L. M. Brus6,
  8. M. A. F. J. van de Laar2,
  9. P. L. C. M. van Riel1,†

Article first published online: 2 SEP 2010

DOI: 10.1002/acr.20211

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 62, Issue 9, pages 1335–1341, September 2010

Additional Information

How to Cite

Blom, M., Kievit, W., Kuper, H. H., Jansen, T. L., Visser, H., den Broeder, A. A., Brus, H. L. M., van de Laar, M. A. F. J. and van Riel, P. L. C. M. (2010), Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res, 62: 1335–1341. doi: 10.1002/acr.20211

Author Information

  1. 1

    Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

  2. 2

    Medisch Spectrum Twente, Enschede, The Netherlands

  3. 3

    Medical Centre Leeuwarden, Leeuwarden, The Netherlands

  4. 4

    Alysis Care Group, Arnhem, The Netherlands

  5. 5

    Sint Maartenskliniek, Nijmegen, The Netherlands

  6. 6

    Twee Steden Hospital, Tilburg, The Netherlands

  1. †

    Dr. van Riel has received consultancy fees, speaking fees, and/or honoraria (less than $10,000 each) from Wyeth, Schering-Plough, Abbott, and Roche.

*Department of Rheumatology, Radboud University Nijmegen Medical Centre, PO Box 9101, H 470, 6500 HB Nijmegen, The Netherlands

  1. †

    Dr. van Riel has received consultancy fees, speaking fees, and/or honoraria (less than $10,000 each) from Wyeth, Schering-Plough, Abbott, and Roche.

Publication History

  1. Issue published online: 2 SEP 2010
  2. Article first published online: 2 SEP 2010
  3. Accepted manuscript online: 9 APR 2010 12:00AM EST
  4. Manuscript Accepted: 31 MAR 2010
  5. Manuscript Received: 9 JAN 2010

Funded by

  • Dutch Rheumatoid Arthritis Monitoring cohort was supported by the Dutch National Health Insurance Board
  • Dutch affiliations of Wyeth, Abbott, Schering-Plough, Roche, UCB, and Bristol-Myers Squibb

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (89K)

REFERENCES

  • 1
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932–9.
  • 2
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675–81.
  • 3
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400–11.
    Direct Link:
  • 4
    Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, et al. The effectiveness and medication costs of three anti-tumour necrosis factor α agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008; 67: 1229–34.
  • 5
    Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1233–8.
  • 6
    Durez P, van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) 2005; 44: 465–8.
  • 7
    Van Vollenhoven RF, Brannemark S, Klareskog L. Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis 2004; 63: 426–30.
  • 8
    Van Vollenhoven RF, Klareskog L. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. Scand J Rheumatol 2007; 36: 418–23.
  • 9
    Pavelka K, Jarosova K, Suchy D, Senolt L, Chroust K, Dusek L, et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomized, double blind study failed to confirm its efficacy. Ann Rheum Dis 2009; 68: 1285–9.
  • 10
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al, for the PREMIER Study Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26–37.
    Direct Link:
  • 11
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24.
    Direct Link:
  • 12
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–8.
    Direct Link:
  • 13
    Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34–40.
    Direct Link:
  • 14
    Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921–6.
  • 15
    Van Vollenhoven RF. How to dose infliximab in rheumatoid arthritis: new data on a serious issue. Ann Rheum Dis 2009; 68: 1237–9.
  • 16
    Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711–5.
    Direct Link:
  • 17
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum 2006; 54: 3782–9.
    Direct Link:
  • 18
    Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739–45.
  • 19
    Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-α biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 2007; 46: 1828–34.
View Full Article (HTML) Get PDF (89K)